Compare Stocks

→ Don’t Miss Out on the AI Gold Rush That’s Just Getting Started (From Banyan Hill Publishing) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYCN Cyclerion Therapeutics	$2.77 -9.2%	$3.10	$1.75 ▼ $6.75	$7.51M	1.84	3,929 shs	132 shs
LCI Lannett		$1.54	$0.64 ▼ $3.72	$7.38M	0.95	92,067 shs	280,600 shs
REPH Recro Pharma		$1.73	$1.38 ▼ $3.79	$117.93M	1.08	126,298 shs	141,800 shs
SNDX Syndax Pharmaceuticals	$20.97 +0.0%	$22.77	$11.22 ▼ $25.34	$1.78B	1.03	1.15 million shs	872,084 shs
ZYNE Zynerba Pharmaceuticals	$1.30 +2.4%	$1.30	$0.25 ▼ $1.40	$70.12M	1.32	515,333 shs	862,700 shs

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYCN Cyclerion Therapeutics	-15.14%	-13.66%	-2.62%	-13.91%	-50.17%
LCI Lannett	0.00%	0.00%	0.00%	0.00%	0.00%
REPH Recro Pharma	0.00%	0.00%	0.00%	0.00%	0.00%
SNDX Syndax Pharmaceuticals	+0.77%	-3.05%	-7.17%	-1.27%	-2.51%
ZYNE Zynerba Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	+225.00%

Don’t Miss Out on the AI Gold Rush That’s Just Getting Started (Ad)

“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.

See how you can invest alongside him

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CYCN Cyclerion Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LCI Lannett	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
REPH Recro Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SNDX Syndax Pharmaceuticals	2.9842 of 5 stars	3.5	1.0	0.0	4.4	0.9	0.0	0.6
ZYNE Zynerba Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CYCN Cyclerion Therapeutics	N/A	N/A	N/A	N/A
LCI Lannett	N/A	N/A	N/A	N/A
REPH Recro Pharma	N/A	N/A	N/A	N/A
SNDX Syndax Pharmaceuticals	2.90	Moderate Buy	$34.42	64.12% Upside
ZYNE Zynerba Pharmaceuticals	2.00	Hold	$1.11	-14.62% Downside

Current Analyst Ratings

Latest REPH, ZYNE, LCI, SNDX, and CYCN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/27/2024	SNDX Syndax Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$41.00
3/20/2024	SNDX Syndax Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$31.00 ➝ $34.00
2/28/2024	SNDX Syndax Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$41.00
1/31/2024	SNDX Syndax Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Sector Outperform ➝ Sector Perform	$36.00 ➝ $23.00

(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CYCN Cyclerion Therapeutics	$1.62M	4.63	N/A	N/A	$4.62 per share	0.60
LCI Lannett	$340.58M	0.00	N/A	N/A	($23.34) per share	0.00
REPH Recro Pharma	$75.36M	0.00	N/A	N/A	$0.90 per share	0.00
SNDX Syndax Pharmaceuticals	$139.71M	12.75	N/A	N/A	$6.53 per share	3.21
ZYNE Zynerba Pharmaceuticals	N/A	N/A	N/A	N/A	$1.01 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CYCN Cyclerion Therapeutics	-$5.26M	-$5.51	N/A	∞	N/A	N/A	-111.79%	-74.10%	5/9/2024 (Estimated)
LCI Lannett	-$231.62M	-$18.88	N/A	N/A	N/A	-62.40%	N/A	-13.39%	N/A
REPH Recro Pharma	-$11.37M	-$0.31	N/A	N/A	N/A	-15.15%	-56.66%	-11.14%	N/A
SNDX Syndax Pharmaceuticals	-$209.36M	-$2.96	N/A	N/A	N/A	N/A	-47.88%	-44.00%	5/13/2024 (Estimated)
ZYNE Zynerba Pharmaceuticals	-$35.04M	-$0.80	N/A	N/A	N/A	N/A	-90.03%	-72.62%	N/A

Latest REPH, ZYNE, LCI, SNDX, and CYCN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
2/27/2024	Q4 2023	SNDX Syndax Pharmaceuticals	-$0.99	-$1.00	-$0.01	-$1.00	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CYCN Cyclerion Therapeutics	N/A	N/A	N/A	N/A	N/A
LCI Lannett	N/A	N/A	N/A	N/A	N/A
REPH Recro Pharma	N/A	N/A	N/A	N/A	N/A
SNDX Syndax Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ZYNE Zynerba Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CYCN Cyclerion Therapeutics	N/A	3.85	3.85
LCI Lannett	N/A	2.23	1.39
REPH Recro Pharma	2.27	3.24	2.74
SNDX Syndax Pharmaceuticals	N/A	10.00	10.00
ZYNE Zynerba Pharmaceuticals	N/A	3.43	3.43

Ownership

Institutional Ownership

Company	Institutional Ownership
CYCN Cyclerion Therapeutics	75.62%
LCI Lannett	40.28%
REPH Recro Pharma	62.34%
SNDX Syndax Pharmaceuticals	N/A
ZYNE Zynerba Pharmaceuticals	11.23%

Insider Ownership

Company	Insider Ownership
CYCN Cyclerion Therapeutics	13.10%
LCI Lannett	13.12%
REPH Recro Pharma	14.20%
SNDX Syndax Pharmaceuticals	4.10%
ZYNE Zynerba Pharmaceuticals	13.04%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
CYCN Cyclerion Therapeutics	1	2.71 million	2.36 million	No Data
LCI Lannett	810	10.77 million	9.35 million	Optionable
REPH Recro Pharma	185	56.42 million	48.41 million	Optionable
SNDX Syndax Pharmaceuticals	184	84.96 million	81.48 million	Optionable
ZYNE Zynerba Pharmaceuticals	25	53.94 million	46.91 million	Optionable

REPH, ZYNE, LCI, SNDX, and CYCN Headlines

Source	Headline
	Harmony Biosciences Reports Strong Third Quarter 2023 Financial Results finance.yahoo.com - October 31 at 7:57 AM
	Why Shares of Harmony Bioscience Are Falling on Friday fool.com - October 13 at 12:59 PM
	New Possibilities For Cannabinoid Treatments: Acquisition To Transform Neuropsychiatric Disorder Therapies markets.businessinsider.com - October 11 at 9:47 AM
	HARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINE finance.yahoo.com - October 11 at 9:47 AM
	H.C. Wainwright analysts reiterates a Buy rating for Zynerba Pharmaceuticals Inc (ZYNE) knoxdaily.com - October 10 at 1:59 PM
	Analysts: ZYNE stock price target of $1.25 in 12 months knoxdaily.com - October 5 at 6:47 PM
	Important Information for Zynerba Pharmaceuticals Stockholders to Tender Shares for the Harmony Transaction: Process and Instructions finance.yahoo.com - October 4 at 7:33 PM
	Examining the Potential Price Growth of Zynerba Pharmaceuticals Inc (ZYNE) knoxdaily.com - October 2 at 3:14 PM
	20 Countries With Highest Rate of Epilepsy finance.yahoo.com - September 29 at 6:24 PM
	Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023 finance.yahoo.com - September 29 at 1:23 PM
	Harmony Biosciences extends deadline for Zynerba shareholders on up to $200M deal bizjournals.com - September 27 at 2:42 PM
	Zynerba Pharmaceuticals Inc [ZYNE] Investment Appeal on the Rise knoxdaily.com - September 25 at 8:15 PM
	Zynerba Pharmaceuticals Inc. (ZYNE) rating reiterates by H.C. Wainwright knoxdaily.com - September 20 at 12:12 PM
	Negative sentiment towards ZYNE reflected in surge in short interest knoxdaily.com - September 15 at 8:27 PM
	Insider Sell: President Terri Sebree Sells 12,401 Shares of Zynerba Pharmaceuticals Inc finance.yahoo.com - September 14 at 11:23 PM
	Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at The Society for the Study of Behavioural Phenotypes (SSBP) 25th International Research Symposium finance.yahoo.com - September 14 at 6:23 PM
	Zynerba Pharmaceuticals Hit With Shareholder Suit in Pa. Over Allegedly Inadequate Proxy Statement law.com - September 11 at 4:04 PM
	Positive sentiment towards ZYNE reflected in decline in short interest knoxdaily.com - September 8 at 5:19 AM
	SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CTG, ZYNE, KLR bakersfield.com - August 31 at 5:00 PM
	HC Wainwright & Co. Downgrades Zynerba Pharmaceuticals (ZYNE) msn.com - August 16 at 4:20 AM
	Harmony Makes Rare Disease Play with Potential $200M Zynerba Buyout biospace.com - August 15 at 6:19 PM
	Zynerba Pharma (NASDAQ: ZYNE) up 300% - The contingents are worth how much? dhakatribune.com - August 15 at 6:19 PM
	Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Deliver On Growth Plans? finance.yahoo.com - August 15 at 6:19 PM
	Zynerba Pharmaceuticals Shares Soar on Harmony Biosciences Deal >ZYNE marketwatch.com - August 14 at 9:48 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Cyclerion Therapeutics

NASDAQ:CYCN

Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Lannett

NYSE:LCI

Lannett Co., Inc. engages in the development, manufacture, marketing, and distribution of generic pharmaceutical products. It offers products in different forms including capsules, tablets, liquids, powders, and sprays. The company was founded in 1942 and is headquartered in Trevose, PA.

Recro Pharma

NASDAQ:REPH

Recro Pharma, Inc. is a pharmaceutical company, which engages in the contract development and manufacturing organization (CDMO). The firm offers integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and development stage oral solid dose drug products. The company was founded by Geraldine A. Henwood and Thomas F. Henwood on November 15, 2007 and is headquartered in Exton, PA.

Syndax Pharmaceuticals

NASDAQ:SNDX

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

Zynerba Pharmaceuticals

NASDAQ:ZYNE

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial